JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Constantine Davides has reiterated a Market Outperform rating on OptimizeRx (NASDAQ: OPRX) and maintained a $16 price target.
June 21, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Constantine Davides has reiterated a Market Outperform rating on OptimizeRx (NASDAQ: OPRX) and maintained a $16 price target.
The reiteration of a Market Outperform rating and the maintenance of a $16 price target by JMP Securities is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100